News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

4SC AG (VSC.F) Says Its Resminostat Meets Primary Endpoint In Phase II Trial



1/19/2012 11:00:19 AM

(RTTNews) - 4SC AG (FSCGF.PK: News ) published encouraging efficacy data from the clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry.

Read at RTT News

Related News

comments powered by Disqus
RTT News
4SC AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES